The UK's innovative life sciences and biotech sector secured its fifth best fundraising year ever in 2022, with £1,785 million raised by UK-headquartered public and private companies across the year. While positive, this overall figure masks a mixed picture for the sector. Capital Markets partner Ariel White-Tsimikalis shares her thoughts on the state of UK IPOs in BIA’s UK Biotech Financing Report 2022. “London currently has the unique opportunity to attract mid-sized UK and European-based biotechs and other life sciences companies who are too big for a listing in mainland Europe but potentially too small for Nasdaq,” said, White-Tsimikalis. “With sharpened regulatory and political focus on bringing more growth capital to the UK markets and more companies successfully using AIM as a stepping stone to Nasdaq and the Main Market, London needs to present itself as a viable alternative destination for biotechs.”